Company Overview
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.19.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +166.89% |
| 6 Months: | +33.82% |
| 3 Months: | +25.16% |
| 1 Month: | +32.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DYN Dyne Therapeutics, Inc. R2K | 23.78 | -7.55 | $3.93B | 0.00% | -41.20% | -58.89% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -3.63M | -7.85M | -8.68M | -13.52M | -25.13M | -30.16M | -42.77M | -35.78M | -52.76M | -42.28M | -45.46M | -66.74M | -62.27M | -69.16M | -71.96M | -105.57M | -122.37M | -115.79M | -113.89M | -125.28M |
| Net Income | -2.09M | -1.50M | -5.87M | -7.89M | -8.98M | -13.92M | -24.97M | -29.95M | -42.58M | -35.58M | -52.30M | -41.38M | -44.19M | -64.90M | -60.21M | -65.65M | -65.10M | -97.12M | -115.36M | -110.86M | -108.04M | -120.85M |
| Diluted EPS | - | - | - | - | - | - | - | -0.58 | -0.83 | -0.69 | -1.01 | -0.80 | -0.78 | -1.08 | -0.99 | -0.81 | -0.70 | -0.96 | -1.05 | -0.97 | -0.76 | -0.73 |
| R&D Expense | - | - | 2.98M | 6.09M | 7.33M | 9.68M | 18.62M | 23.87M | 36.51M | 28.24M | 46.66M | 34.67M | 37.54M | 59.13M | 55.25M | 44.54M | 62.26M | 92.80M | 106.45M | 99.24M | 97.22M | 100.89M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -13.83M | -58.65M | -150.03M | -170.96M | -242.16M | -343.89M | -468.18M |
| Net Income | -14.86M | -59.44M | -149.29M | -168.10M | -235.94M | -317.42M | -446.21M |
| Diluted EPS | - | - | -2.93 | -3.23 | -3.95 | -3.37 | -3.47 |
| R&D Expense | 11.04M | 45.20M | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 16.44M | 353.33M | 425.66M | 306.32M | 165.08M | 691.23M | 1.19B |
| Total Equity | -4.88M | 14.04M | 342.37M | 368.20M | 252.36M | 91.29M | 629.84M | 972.13M |
| Cash & Equivalents | - | 14.63M | 300.85M | 200.82M | 172.15M | 121.63M | 435.45M | 893.37M |
| Long Term Debt | - | - | - | - | - | - | 0 | 148.92M |
| Total Liabilities | - | 2.40M | 10.97M | 57.47M | 53.96M | 73.79M | 61.40M | 214.83M |
| Current Liabilities | - | 2.36M | 10.97M | 28.72M | 28.09M | 51.09M | 42.26M | 50.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.83M | -46.51M | -119.56M | -153.65M | -188.16M | -292.37M | -403.21M |
| Investing Cash Flow | -1.65M | -45.66M | -137.89M | 87.20M | 83.31M | -204.08M | -28.75M |
| Financing Cash Flow | 19.99M | 380.69M | 157.82M | 37.39M | 54.32M | 809.89M | 890.31M |
| Capital Expenditure | -1.65M | -1.16M | -3.62M | -3.07M | -729.00K | -2.38M | -1.92M |
| Free Cash Flow | -13.48M | -47.67M | -123.18M | -156.71M | -188.89M | -294.75M | -405.13M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | -105.9% | -17.4% | -40.5% | -66.6% | -258.4% | -50.4% | -45.9% |
| ROCE % | -98.2% | -17.1% | -37.8% | -61.4% | -212.4% | -53.0% | -41.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 18.62% | 30.79M | $693.60M |
| 2 | Janus Henderson Group PLC | 8.26% | 13.65M | $307.48M |
| 3 | Blackrock Inc. | 7.08% | 11.70M | $263.60M |
| 4 | Atlas Venture Life Science Advisors, LLC | 5.52% | 9.13M | $205.71M |
| 5 | FMR, LLC | 5.39% | 8.91M | $200.72M |
| 6 | Orbis Allan Gray Ltd | 4.09% | 6.76M | $152.35M |
| 7 | State Street Corporation | 4.02% | 6.65M | $149.91M |
| 8 | Vanguard Capital Management LLC | 3.87% | 6.41M | $144.31M |
| 9 | Perceptive Advisors Llc | 2.82% | 4.67M | $105.19M |
| 10 | FCPM III Services B.V. | 2.81% | 4.64M | $104.64M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DYN
DYN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5OR2xIM09DelVnUnlpX01Dcy15LWNfaTY3VnkwUVdfTFQ0UHM0QkFHZ29SQlllRmdzMGRldmlNQlNQUGhxUWlJLUZ0amUtblhFSFBNeHJab3ZYYlcyandpTzVBRjVvaFlFYnNYNjhobTBham9hbXhjSA?oc=5" target="_blank">DYN F…
Dyne Therapeutics(DYN.US) Director Sells US$17.86 Million in Common Stock - Moomoo
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNZ0pxUTRiV1pfcndMQUdYeEcyR0hrU1FYeDFoRlk3WnR1djVqdEtlSXAtX29xNDU3U25mWmk2dU1tY1VxdTZvTjdmM3k0RWRBRDhrbDRzazZzb1B0UHlVYUphVFpXdm5ESV8zX004TEl3dW9OcFRUSlRhNVlrOFloTEZpenk5dnhqMHJnSn…
Dyne Therapeutics (DYN) director-linked Atlas funds sell 777K shares under 10b5-1 plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNTDN5X3AyTXZ1bmxmY2VjVDM2OG5KNHhrRmM0WUtzaFhkcExoRkNwWkozMzRkejN1alg3RjBITVpSWUM0LUZhekR1cVVyc0I1d3Fjd3k0bE1OcjM4Ukk4dXdZRzJmQ1ZKWjAwSDZWcGZGUjltMjdVekZpVjA4aUFVVDZSOGJlUXdZUDNFcG…
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPZTBZR05ielZ2c1lvQnFtZlZqMW13WUl2M0ROd0RsTVJKN0UzbHFNTVBteVV2cHFmWWpZclJ0RmE4X21RNDlER1JuVkNmaE50S2VCSHpwbjZiUWZ5YXFsMlFXb3QzeUk0Vmw2SjBXQk53aVIzYVdWVGJ6cVU4WWhSZnAwaFU?oc=5" targ…
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQUXZINmxzaGplZGJQRGlDUnZMa01lY1VrUThiUW1UQ0o0OVVES3ZaZmpGMFdWZVdwWE1lRHBmODNyQTVSc0JPWmY5c2NSd2hzWFI2R2ZnN2x3WDZpbmNROG9TTUpsNU9lWEtPbGRJeE5McGFENW1kZTFqMWRfbzZwVmVsSWlyY0tfcTNKTG…
$DYN stock is up 18% today. Here's what we see in our data. | DYN Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNeTh4SFBlWjlrNjQySktrbWt2cWdObUVWYzhrbjd2cC1hR0QzZ091WXhpTkU0RGtwOW5qd0huYUoyeTl2TE54cnNFRGU2U3diMWVxRHhpNkFaTm04bHpUWEpkU1hkQWotczB6Y0k3Ynd3V1UwMlVTbC1VTkl5NU9JSnZ6N1FYc01rZlNGSW…
DYN — Frequently Asked Questions
What is the current share price of Dyne Therapeutics, Inc. (DYN)?
As of 2026-07-14 21:23 PDT, Dyne Therapeutics, Inc. (DYN) trades at $23.78 on NasdaqGS. Its 52-week range is $8.28 to $24.29.
What is the market capitalisation of DYN?
Dyne Therapeutics, Inc. (DYN) has a market capitalisation of $3.93B on NasdaqGS.
What is the P/E ratio of DYN?
DYN trades at a trailing price-to-earnings (P/E) ratio of -7.55. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.47.
What is the return on equity (ROE) of DYN?
DYN has a return on equity (ROE) of -58.89%. Its return on capital employed (ROCE) is -41.20%.
Is DYN a good stock to buy?
This page provides a data-driven analysis of Dyne Therapeutics, Inc. (DYN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.